Matches in SemOpenAlex for { <https://semopenalex.org/work/W4301876841> ?p ?o ?g. }
Showing items 1 to 95 of
95
with 100 items per page.
- W4301876841 endingPage "2090" @default.
- W4301876841 startingPage "2083" @default.
- W4301876841 abstract "BACKGROUND Docetaxel and vinorelbine are active agents in the treatment of nonsmall cell lung carcinoma (NSCLC). The efficacy and toxicity of this combination was evaluated in a Phase II study in patients with advanced NSCLC. METHODS Forty-six chemotherapy-naive patients (44 men and 2 women with a median age of 64 years) with NSCLC (11 with Stage IIIB and 35 with Stage IV disease) were entered into the study; the World Health Organization (WHO) performance status was 0, 1, and 2 in 32, 11, and 3 patients, respectively. Patients received vinorelbine (25 mg/m2) on Day 1 and docetaxel (100 mg/m2) on Day 2 in cycles repeated every 3 weeks. Granulocyte-colony stimulating factor was given to all patients from Day 3 to Day 10. RESULTS One hundred and seventy-seven courses of chemotherapy were administered. Adverse events included WHO Grade 4 neutropenia (15 patients), Grade 3/4 thrombocytopenia (3 patients), Grade 3 anemia (2 patients), Grade 2 and 3 neurotoxicity (7 patients and 1 patient, respectively), and Grade 3 fatigue (2 patients). Twenty patients (43%) required hospitalization: 11 (24%) for neutropenic fever (2 deaths from sepsis), and 9 (20%) for nonneutropenic pulmonary infections (2 deaths from cardiopulmonary insufficiency). The median overall survival was 5 months and the 1-year survival was 24%. Four complete responses (9.8%) and 11 partial responses (26.8%) (overall response rate of 36.6%; 95% confidence interval, 21.8-51.3%) were documented in 41 evaluable patients (intent-to-treat: 32.6%). Stable and progressive disease occurred in 13 patients each (31.7%). The median duration of response was 5 months and the median time to progression was 3 months (6 months for the responders). CONCLUSIONS This schedule of docetaxel and vinorelbine combination is effective but its relatively high incidence of complicated neutropenia precludes its general use in patients with advanced NSCLC. Cancer 1998;83:2083-2090. © 1998 American Cancer Society." @default.
- W4301876841 created "2022-10-05" @default.
- W4301876841 creator A5006588136 @default.
- W4301876841 creator A5010312876 @default.
- W4301876841 creator A5010790219 @default.
- W4301876841 creator A5026478600 @default.
- W4301876841 creator A5027287036 @default.
- W4301876841 creator A5027807165 @default.
- W4301876841 creator A5068888404 @default.
- W4301876841 creator A5072698609 @default.
- W4301876841 creator A5078192662 @default.
- W4301876841 creator A5084377238 @default.
- W4301876841 date "1998-11-15" @default.
- W4301876841 modified "2023-09-27" @default.
- W4301876841 title "First-line treatment of advanced nonsmall cell lung carcinoma with docetaxel and vinorelbine" @default.
- W4301876841 cites W1826360242 @default.
- W4301876841 cites W1922104747 @default.
- W4301876841 cites W1964842293 @default.
- W4301876841 cites W1972010711 @default.
- W4301876841 cites W2001566158 @default.
- W4301876841 cites W2016263166 @default.
- W4301876841 cites W2043478531 @default.
- W4301876841 cites W2058978290 @default.
- W4301876841 cites W2073129008 @default.
- W4301876841 cites W2073533584 @default.
- W4301876841 cites W2128746268 @default.
- W4301876841 cites W2129793485 @default.
- W4301876841 cites W2167805334 @default.
- W4301876841 cites W2256453366 @default.
- W4301876841 cites W2399967941 @default.
- W4301876841 cites W4239714259 @default.
- W4301876841 cites W4293241248 @default.
- W4301876841 doi "https://doi.org/10.1002/(sici)1097-0142(19981115)83:10<2083::aid-cncr6>3.0.co;2-i" @default.
- W4301876841 hasPublicationYear "1998" @default.
- W4301876841 type Work @default.
- W4301876841 citedByCount "31" @default.
- W4301876841 crossrefType "journal-article" @default.
- W4301876841 hasAuthorship W4301876841A5006588136 @default.
- W4301876841 hasAuthorship W4301876841A5010312876 @default.
- W4301876841 hasAuthorship W4301876841A5010790219 @default.
- W4301876841 hasAuthorship W4301876841A5026478600 @default.
- W4301876841 hasAuthorship W4301876841A5027287036 @default.
- W4301876841 hasAuthorship W4301876841A5027807165 @default.
- W4301876841 hasAuthorship W4301876841A5068888404 @default.
- W4301876841 hasAuthorship W4301876841A5072698609 @default.
- W4301876841 hasAuthorship W4301876841A5078192662 @default.
- W4301876841 hasAuthorship W4301876841A5084377238 @default.
- W4301876841 hasConcept C126322002 @default.
- W4301876841 hasConcept C141071460 @default.
- W4301876841 hasConcept C2776256026 @default.
- W4301876841 hasConcept C2776694085 @default.
- W4301876841 hasConcept C2776907518 @default.
- W4301876841 hasConcept C2777063308 @default.
- W4301876841 hasConcept C2778239845 @default.
- W4301876841 hasConcept C2778248108 @default.
- W4301876841 hasConcept C2778822529 @default.
- W4301876841 hasConcept C2778850193 @default.
- W4301876841 hasConcept C2780350996 @default.
- W4301876841 hasConcept C2781190966 @default.
- W4301876841 hasConcept C71924100 @default.
- W4301876841 hasConcept C90924648 @default.
- W4301876841 hasConceptScore W4301876841C126322002 @default.
- W4301876841 hasConceptScore W4301876841C141071460 @default.
- W4301876841 hasConceptScore W4301876841C2776256026 @default.
- W4301876841 hasConceptScore W4301876841C2776694085 @default.
- W4301876841 hasConceptScore W4301876841C2776907518 @default.
- W4301876841 hasConceptScore W4301876841C2777063308 @default.
- W4301876841 hasConceptScore W4301876841C2778239845 @default.
- W4301876841 hasConceptScore W4301876841C2778248108 @default.
- W4301876841 hasConceptScore W4301876841C2778822529 @default.
- W4301876841 hasConceptScore W4301876841C2778850193 @default.
- W4301876841 hasConceptScore W4301876841C2780350996 @default.
- W4301876841 hasConceptScore W4301876841C2781190966 @default.
- W4301876841 hasConceptScore W4301876841C71924100 @default.
- W4301876841 hasConceptScore W4301876841C90924648 @default.
- W4301876841 hasIssue "10" @default.
- W4301876841 hasLocation W43018768411 @default.
- W4301876841 hasOpenAccess W4301876841 @default.
- W4301876841 hasPrimaryLocation W43018768411 @default.
- W4301876841 hasRelatedWork W1903273130 @default.
- W4301876841 hasRelatedWork W1983042427 @default.
- W4301876841 hasRelatedWork W1983629809 @default.
- W4301876841 hasRelatedWork W1987606751 @default.
- W4301876841 hasRelatedWork W2003291927 @default.
- W4301876841 hasRelatedWork W2028358976 @default.
- W4301876841 hasRelatedWork W2183888492 @default.
- W4301876841 hasRelatedWork W2351763027 @default.
- W4301876841 hasRelatedWork W4231397873 @default.
- W4301876841 hasRelatedWork W4301876841 @default.
- W4301876841 hasVolume "83" @default.
- W4301876841 isParatext "false" @default.
- W4301876841 isRetracted "false" @default.
- W4301876841 workType "article" @default.